Intensity-Modulated Radiotherapy with Concomitant Boost After Breast Conserving Surgery: A Phase I-II Trial

Gabriella Macchia, Savino Cilla, Milly Buwenge, Alice Zamagni, Ilario Ammendolia, Claudio Zamagni, Giovanni P Frezza, Vincenzo Valentini, Francesco Deodato, Alessio G Morganti, Gabriella Macchia, Savino Cilla, Milly Buwenge, Alice Zamagni, Ilario Ammendolia, Claudio Zamagni, Giovanni P Frezza, Vincenzo Valentini, Francesco Deodato, Alessio G Morganti

Abstract

Purpose: A concomitant boost (CB) in patients treated with postoperative radiotherapy after conservative surgery of invasive breast cancer (BC) has been suggested for treatment time reduction and therapy intensification. The aim of this analysis was to assess long-term tolerability of a CB in patients treated with postoperative intensity Modulated Accelerated RAdiotherapy (MARA).

Patients and methods: In this phase I-II trial, 321 patients with intermediate-high risk BC (pT1-4 with at least one of the following characteristics: pre or perimenopausal status, pN2-3, positive or close margins) were enrolled. Patients were treated with forward-planned intensity modulated radiotherapy (IMRT) and CB. A total dose of 50 Gy (2 Gy/fraction) and 60 Gy (2.4 Gy/fraction) was prescribed to the whole breast and the tumor bed, respectively. The potential impact of hypertension, diabetes, smoking habit, alcohol consumption, chemotherapy, and hormone therapy on both skin and subcutaneous late toxicity-free survival (LTFS) was evaluated. Survival curves were calculated using the Kaplan-Meier method.

Results: Median follow-up was 52 months (range: 3-115). Regional node irradiation, adjuvant chemotherapy and hormonal therapy were prescribed to 29.3%, 65.4% and 81.0% of patients, respectively. Five-year G2 and G3 skin LTFS were 95.6% and 100.0%, respectively. Five-year G2 and G3 subcutaneous LTFS were 80.0% and 98.6%, respectively. Only diabetes showed a significant correlation with worse G3 subcutaneous LTFS (p: 0.024). Five-year loco-regional control, metastasis-free survival, disease-free survival, and overall survival were 98.0%, 91.8%, 89.7% and 96.3%, respectively.

Conclusion: IMRT combined with CB was associated with a low risk of > G2 late toxicities (0.0% and 1.4% for skin and subcutaneous tissue, respectively). The cumulative actuarial incidence of local recurrences was 2.0% despite the exclusion of low-risk patients. Our results suggest that CB is safe and effective in patients with intermediate-high risk BC.

Trial registration: ClinicalTrials.gov: NCT03471741.

Keywords: IMRT; adjuvant radiotherapy; breast cancer; concomitant boost; toxicity.

Conflict of interest statement

Claudio Zamagni reports grants, personal fees, and non-financial support from Roche, Novartis, AstraZeneca, and Pfizer, grants from Eisai, PharmaMar, Celgene, lilly, Amgen, Pierre Fabre, Takeda, TEVA, Medivation, Array BioPharma, Abbvie, Morphotek, Synthon, Seattle Genetics, Daiichi and Sankyo, grants and personal fees from Tesaro, personal fees from QuintilesIMS, and travel accommodation and research funding from Istituto Gentili, outside the submitted work. Alessio G. Morganti reports grants from Elekta, Beyer, and IGEA and personal fees from Astellas and Alfa-Sigma, outside the submitted work. The authors report no other potential conflicts of interest in this work.

© 2020 Macchia et al.

References

    1. Female Breast Cancer - Cancer Stat Facts. Available from: . Accessed March30, 2020.
    1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241. doi:10.1056/NEJMoa022152
    1. Veronesi U, Cascinell N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232. doi:10.1056/NEJMoa020989
    1. Macdonald S, Oncology R, General M. Breast cancer. Available from:
    1. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–v30. doi:10.1093/annonc/mdv298
    1. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised Phase 3 trial. Lancet Oncol. 2015;16:47–56. doi:10.1016/S1470-2045(14)71156-8
    1. Buwenge M, Cammelli S, Ammendolia I, et al. Intensity modulated radiation therapy for breast cancer: current perspectives. Breast Cancer. 2017;9:121–126.
    1. Freedman GM, White JR, Arthur DW, Allen Li X, Vicini FA. Accelerated fractionation with a concurrent boost for early stage breast cancer. Radiother Oncol. 2013;106(1):15–20. doi:10.1016/j.radonc.2012.12.001
    1. Franco P, Cante D, Sciacero P, Girelli G, La Porta MR, Ricardi U. Tumor bed boost integration during whole breast radiotherapy: A review of the current evidence. Breast Care. 2015;10:44–49. doi:10.1159/000369845
    1. Hamilton DG, Bale R, Jones C, et al. Impact of tumour bed boost integration on acute and late toxicity in patients with breast cancer: A systematic review. Breast. 2016;27:126–135. doi:10.1016/j.breast.2016.03.002
    1. Morganti AG, Cilla S, Valentini V, et al. Phase I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients. Radiother Oncol. 2009;90:86–92. doi:10.1016/j.radonc.2008.10.017
    1. International Commission on Radiation Units and Measurements. ICRU Report 62. Prescribing, Recording, and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). Bethesda, MD: ICRU; 1999.
    1. Morganti AG, Deodato F, Zizzari S, et al. Complexity index (COMIX) and not type of treatment predicts undetected errors in radiotherapy planning and delivery. Radiother Oncol. 2008;89:320–329. doi:10.1016/j.radonc.2008.07.009
    1. Deodato F, Cilla S, Massaccesi M, et al. Daily on-line set-up correction in 3d-conformal radiotherapy: is it feasible? Tumori. 2012;98:441–444. doi:10.1177/030089161209800407
    1. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346. doi:10.1016/0360-3016(95)00060-C
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi:10.1080/01621459.1958.10501452
    1. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc. 1972;135:185–207.
    1. McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PAS. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. 2010;77:523–530. doi:10.1016/j.ijrobp.2009.05.042
    1. Bantema-Joppe EJ, Schilstra C, De Bock GH, et al. Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months’ follow-up. Int J Radiat Oncol Biol Phys. 2012;83:e471–e477. doi:10.1016/j.ijrobp.2012.01.050
    1. Corvò R, Ricchetti F, Doino D, et al. Adjuvant hypofractionated radiotherapy with weekly concomitant boost for women with early breast cancer: the clinical experience at Genoa university. Anticancer Res. 2010;30:4749–4753.
    1. Teh AYM, Walsh L, Purdie TG, et al. Concomitant intensity modulated boost during whole breast hypofractionated radiotherapy - A feasibility and toxicity study. Radiother Oncol. 2012;102:89–95. doi:10.1016/j.radonc.2011.10.015
    1. Bantema-Joppe EJ, Vredeveld EJ, De Bock GH, et al. Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; Patterns of recurrence. Radiother Oncol. 2013;108:269–272. doi:10.1016/j.radonc.2013.08.037
    1. Raza S, Lymberis SC, Ciervide R, et al. Comparison of acute and late toxicity of two regimens of 3- and 5-week concomitant boost prone IMRT to standard 6-week breast radiotherapy. Front Oncol. 2012;2:1–10.
    1. Cante D, Franco P, Sciacero P, et al. Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Med Oncol. 2013;30:518. doi:10.1007/s12032-013-0518-7
    1. Alford SL, Prassas GN, Vogelesang CR, Leggett HJ, Hamilton CS. Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives. J Med Imaging Radiat Oncol. 2013;57:222–229. doi:10.1111/j.1754-9485.2012.02473.x
    1. Osa EOO, Dewyngaert K, Roses D, et al. Prone breast intensity modulated radiation therapy: 5-year results. Int J Radiat Oncol Biol Phys. 2014;89:899–906. doi:10.1016/j.ijrobp.2014.03.036
    1. Chadha M, Woode R, Sillanpaa J, et al. Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost. Int J Radiat Oncol Biol Phys. 2013;86:40–44. doi:10.1016/j.ijrobp.2012.11.010
    1. Formenti SC, Gidea-Addeo D, Goldberg JD, et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007;25:2236–2242. doi:10.1200/JCO.2006.09.1041
    1. Freedman GM, Anderson PR, Bleicher RJ, et al. Five-year local control in a Phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;84:888–893. doi:10.1016/j.ijrobp.2012.01.091
    1. Cante D, Petrucci E, Sciacero P, et al. Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer. Med Oncol. 2017;34:152. doi:10.1007/s12032-017-1020-4
    1. De Rose F, Fogliata A, Franceschini D, et al. Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. Breast. 2018;42:31–37. doi:10.1016/j.breast.2018.08.098

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj